Dermalax Deep Plus 1.1ml — Monophasic HA for Moderate-to-Deep Wrinkles & Contouring

Dermalax Deep Plus is Across Co.’s mid-range variant — 24 mg/mL monophasic cross-linked HA + 0.3% lidocaine with medium particle size. Engineered for mid-to-deep dermal placement targeting moderate-to-deep nasolabial folds, forehead lines, lip augmentation, and cheek contouring. CE marked with 14–15 day dialysis purification ensuring BDDE residue under 0.5 ppm.

Dermalax Deep Plus 1.1ml Filler is manufactured by Across Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Dermalax dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Dermalax Deep Plus 1.1ml Filler contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Across Co. Ltd.’s Monophasic Cross-Linked HA (Deep Plus Grade) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Across Co. Ltd.’s clinical data, Dermalax Deep Plus 1.1ml Filler delivers 9–12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Dermalax Deep Plus 1.1ml Filler is engineered for mid to deep dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Dermalax Deep Plus 1.1ml Filler regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Dermalax Deep Plus 1.1ml Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Dermalax Deep Plus 1.1ml Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Dermalax Deep Plus 1.1ml Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Dermalax Deep Plus is KFDA registered in South Korea and CE marked for the EU market. It is not currently FDA approved for the US market. Across Co.’s purification process (14–15 day dialysis) ensures BDDE residue undetectability and endotoxin under 0.10 EU/mL — within the international safety thresholds for injectable HA dermal fillers. Practitioners should verify regulatory status in their specific jurisdiction before clinical use.